Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.56 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | BID | P55957 | 1/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.49 |
| ▸ | CNKSR1 | Q969H4 | 3/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241702 | 0.86 | BCL2A1 (0.66) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL10058097 | 0.82 | BRAF (0.56) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL2244161 | 0.82 | MCL1 (0.75) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL10058118 | 0.78 | ALDH1A1 (0.67) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL12352072 | 0.77 | BRAF (0.73) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL14851511 | 0.76 | BRAF (0.60) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL13299611 | 0.74 | KMT2A (0.53) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL2240512 | 0.74 | MCL1 (0.77) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL2242434 | 0.74 | BRAF (0.55) | BRAFBCL2A1BCL2BIDBCL2L1 | |
| SCHEMBL12351812 | 0.73 | BRAF (0.60) | BRAFBCL2A1BCL2BIDBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | BRAF 1168/4885BCL2A1 84/4885BCL2 50/4885 |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | PSMB4, PSME4, PSMB1 | BRAF 2332/4885BCL2A1 1893/4885BCL2 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.